A B S T R A C T The effects of parathyroid hormone (PTH) on plasma and urinary adenosine 3',5'-monophosphate (cyclic AMP) levels were studied in normal subjects. Under basal conditions normal adults have plasma concentrations of cyclic AMP ranging from 10 to 25 nmoles/liter and excrete from 1.5 to 5 imoles of cyclic AMP per g of urinary creatinine. About one-half to two-thirds of the cyclic AMP excreted in the urine is derived from the plasma by glomerular filtration, and the remainder is produced by the kidney. Renal production of cyclic AMP is partly under the control of PTH. It can be suppressed by infusions of calcium and stimulated by infusions of the calcium chelating agent, EDTA. Infusions of PTH in doses up to 10 mU/kg per min were associated with dose-related increases both in urinary cyclic AMP and phosphate. Infusions of PTH in doses ranging from 20 to 80 mU/kg per min did not lead to any further increase in phosphaturia but did lead to further marked increases in urinary cyclic AMP. A modest increase in plasma cyclic AMP was noted when PTH was infused at 40 mU/kg per min. Anephric patients failed to show appreciable increases in plasma cyclic AMP in response to large doses of PTH but did show expected increases in response to glucagon. Surgical removal of parathyroid adenomas from nine patients with primary hyperparathyroidism was invariably followed by a decrease in urinary cyclic This work was presented in part at the 61st Annual
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INTRODUCTION
With the rapid accumulation of evidence that adenosine 3',5'-monophosphate (cyclic AMP) is the intracellular mediator of the action of several hormones (1, 2) , it has seemed pertinent to inquire whether hormonallyinduced increases in tissue cyclic AMP might be reflected in increases in plasma or urinary cyclic AMP. Parathyroid hormone (PTH) stimulates the accumulation of cyclic AMP in broken and unbroken cell preparations of bone and kidney and also increases the excretion of cyclic AMP in the urine (3) (4) (5) (6) (7) (8) . It has been shown in a companion paper (9) Subjects and procedures. PTH, calcium chloride, or sodium EDTA was infused intravenously into healthy men, 20-30 yr of age, who had neither eaten nor smoked for at least 6 hr before study. Hydration was accomplished by having the subjects drink water and by administering 0.45% sodium chloride by intravenous infusion. Urine output exceeded 7 ml/min, and voided urine collections were made with the subjects recumbent. Blood specimens for analysis were obtained through a catheter placed in the antecubital vein in the arm opposite the infusion site. Heparin was used as an anticoagulant. Blood and urine samples were obtained at 15-, 20-, or 30-min intervals. When inulin clearance was measured, a priming dose of 50 mg/kg was followed by an inulin infusion designed to produce a plasma concentration of 0.25 mg/ml. 30-60 min were allowed for equilibration before the beginning of the first control period. Urine specimens were frozen until analyzed. Blood specimens were centrifuged, and the plasma was separated and frozen for subsequent chemical analysis. Cyclic AMP, cyclic GMP, creatinine, and inulin were determined by methods outlined elsewhere (9, 10 
RESULTS
Effects of PTH on plasma and urinary cyclic AMP, and urinary cyclic GMP and phosphate PTH infusions into normal subjects produced increases in urinary cyclic AMP excretion and, to a lesser degree, in plasma cyclic AMP concentrations. The dose-response relationship in one subject studied on different occasions is illustrated in Fig. 1 Since it is probable that PTH-induced phosphaturia is mediated by renal cyclic AMP (3, 6-8), the relationship between cyclic AMP and phosphate in urine after treatment with PTH was also investigated (Fig. 1 Fig. 2 . During control periods cyclic AMP clearance exceeded inulin clearance, the clearance ratio (cyclic AMP: inulin) being about 1.5. In related studies (9) it was determined that circulating cyclic AMP is cleared by glomerular filtration at the same rate as inu- (Fig. 2) . Although PTH and glucagon both raised urinary cyclic AMP levels, it appeared that PTH did so principally by inducing an increase in nephrogenous cyclic AMP while glucagon did so principally by inducing an increase in plasma cyclic AMP (10) .
When very large doses of PTH were infused (80-160 mU/kg per min), there was an initial peak in urinary cyclic AMP followed by a slightly lower plateau still well above control levels. This phenomenon was not observed with low doses of PTH, which induced 2-fold increases in cyclic AMP with a simple plateau configuration.
The source of PTH-induced increases in plasma cyclic AMP When large doses of PTH were infused into normal subjects, there ensued not only a large increase in urinary cyclic AMP but a modest increase in plasma cyclic AMP as well. This increase in plasma cyclic AMP could have been due solely to increased release of cyclic AMP into the circulation by the kidney. However, PTH is also known to act on other tissues, e.g., bone and intestine; therefore, it was equally conceivable that the PTH-induced increase in plasma cyclic AMP might have been of extrarenal origin. In order to investigate these alternatives, comparative studies were performed in normal and anephric subjects (Fig. 3) (Fig. 4) and the clearance ratio (cyclic AMP: inulin) dropped about 50%, indicating a great reduction in the nephrogenous contribution to urinary cyclic AMP. Cyclic GMP excretion was also measured in one of these two subjects (T.C.), and in three additional subjects both plasma and urinary cyclic GMP were determined. In contrast to cyclic AMP, plasma and urinary cyclic GMP rose during calcium infusion (Fig. 5) . The variability in the plasma cyclic GMP determinations was such that it was not possible to be certain whether or not all of the increment in urinary cyclic GMP was derived from plasma. (Fig. 6) . Lowest values were usually observed within 1 day after the operation, after which cyclic AMP excretion gradually rose, but never to preoperative values. In three patients, plasma cyclic AMP determinations were obtained, and the preoperative clearance ratios (cyclic AMP: creatinine) were considerably higher (4.96, 2.80, 2.76) than those seen in normal subjects (9) . Studies in patients undergoing other surgical procedures have indicated no consistent decrease in cyclic AMP excretion during the postoperative period. It is inferred that the decrease observed in the nine patients with hyperparathyroidism was a consequence of a decrease in their secretion of PTH. All nine patients were apparently cured of their hyperparathyroidism, judging from the fact that their serum calcium -concentrations fell to normal. An additional patient (No. 10) had hypercalcemia in association with a carcinoma of the lung. His urinary cyclic AMP was elevated. Irradiation of the tumor resulted in a marked decrease in the size of the tumor, and the serum calcium and urinary cyclic AMP values both fell to normal.
DISCUSSION
In 1962 Butcher and Sutherland demonstrated the presence of cyclic AMP in human urine (16) . 5 yr later Chase and Aurbach found that urinary cyclic AMP in rat and man rose in response to PTH (6) . They also demonstrated a PTH-sensitive adenyl cyclase in the cortical portion of the rat kidney (8), while Rasmussen and Tenenhouse were able to demonstrate cyclic AMP accumulation in the rat kidney after PTH infusion (17) . It was then shown that the dibutyryl derivative of cyclic AMP mimics the actions of PTH on serum calcium and on the urinary excretion of phosphate (18, 19) and hydroxyproline (18) . Vaes demonstrated that dibutyryl cyclic AMP had an effect similar to that of PTH on bone explants (20) . Recently it has been shown by Chase, Fedak, and Aurbach that PTH stimulates bone adenyl cyclase and the accumulation of cyclic AMP in fetal rat calvaria (4, 5) . These observations are consistent with the view that a principal action of PTH is to stimulate adenyl cyclase in its target tissues and that the cyclic AMP that is formed in response to this action is responsible for the various metabolic effects of PTH.
It has been suggested that PTH might be the major determinant of urinary cyclic AMP in the rat (6), but this suggestion has not been supported by other studies (21) . The evidence developed in the present paper and a companion paper (9) indicates that most of the cyclic AMP that appears in the urine is derived from the plasma by glomerular filtration and that this process is not under the control of physiologic levels of PTH. On the other hand, that portion of the urinary cyclic AMP that is added directly by the kidney may be in part under the control of PTH. Simultaneous inulin and cyclic AMP clearance studies indicate that the prolonged infusion of calcium diminishes the excretion of nephrogenous cyclic AMP, suggesting that some of the cyclic AMP which is formed by the kidney and excreted directly into the urine is under the regulatory control of PTH.
Although it is possible to decrease nephrogenous cyclic AMP by infusing calcium, it has not been possible to bring the cyclic AMP: inulin clearance ratio to unity. Thus, even during prolonged calcium infusions, the kidney still makes a small contribution to urinary cyclic AMP. Perhaps this is attributable to difficulty in suppressing endogenous PTH with calcium, but another possibility is that the kidney forms some cyclic AMP through a mechanism that is not PTH dependent. A generally recognized phenomenon in hormone assay work is the "plateauing" of dose-response curves. With the administration of progressively larger doses of a hormone, a point is reached in the dose-response curve beyond which further increments in dosage do not include further increments in target cell response. What it is that limits the responsiveness of a target cell to a hormone has never been clearly defined. In the present studies a plateau in the phosphaturic response curve was reached with a PTH dose of 10 mU/kg per min. By contrast, the cyclic AMP response curve was still rising steeply with a PTH dose of 80 mU/kg per min. This would suggest that the limiting factor in the phosphaturic response of PTH was beyond the formation of cyclic AMP. Analogous observations have been made in studies of other tissues (23, 24) .
Another phenomenon encountered during these studies which also is of general interest was the character of the time-course response to large doses of PTH. An initial high peak in cyclic AMP excretion was followed by a somewhat lower plateau. This pattern of peak followed by plateau has also been observed in other studies of cyclic AMP (10, 25, 26) .
It is possible that measurements of plasma and urinary cyclic AMP might provide useful diagnostic information in certain clinical disorders. In our experience, hyperparathyroidism has been associated with an abnormally high rate of cyclic AMP excretion. The utility of this finding is now undergoing evaluation, and no firm conclusions are justified at this time.
The possibility that cyclic GMP may be involved with calcium balance is raised by the observation that calcium infusions caused urinary and plasma cyclic GMP to rise. Cyclic GMP excretion was increased slightly by very large doses of PTH, but not by small doses of PTH. Whether or not the rise in cyclic GMP excretion that occurred in response to PTH could have been secondary to changes in calcium seems open to question since plasma calcium was not detectably elevated. The hypothesis that the cyclic GMP response might have been mediated by an increase in thyrocalcitonin production was investigated in an ancillary study and was shown to be untenable (27) .
